October 1, 2024
Lexaria Appoints Michael Shankman as Chief Financial Officer
September 5, 2024
Lexaria Welcomes Industry Veteran as New CEO
No current content.
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio. For more information, please visit www.lexariabioscience.com.
October 1, 2024
September 5, 2024
No current content.